Avidity Biosciences, 发展RNA治疗, 获得强烈的“买入”评级, 可能超过230%的增益。 Avidity Biosciences, developing RNA treatments, receives strong "buy" rating with potential for over 230% gain.

Avidity Biosciences是一家在NASDAQ上市的生物制药公司,它从分析家那里获得了强烈的“买入”评级,一致商定的目标价格为65.59美元,从目前价格中可能得到230.69%的收益。 Avidity Biosciences, a biopharmaceutical firm listed on NASDAQ, has garnered a strong "buy" rating from analysts, with a consensus target price of $65.59 and a potential upside of 230.69% from its current price. 该公司正在研制RNA治疗设备,包括处于第1/2阶段试验的第1类心电图萎缩类的牵头产品。 The company is developing RNA therapeutics, including its lead product for myotonic dystrophy type 1, which is in phase 1/2 trials. 尽管净利和股权回报率为负, 但Avidity的市值为35亿美元. Despite a negative net margin and return on equity, Avidity's market cap stands at $3.50 billion.